These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 33491653)

  • 1. Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma.
    Sondak VK; Messina JL; Tarhini AA
    J Am Coll Surg; 2020 Nov; 231(5):554-556. PubMed ID: 33491653
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.
    Koon HB; Atkins MB
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):79-88. PubMed ID: 17187522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tackling melanoma by adjuvant therapy: why, whom and how?
    Schilling B; Wiesner T
    Br J Dermatol; 2019 Jan; 180(1):1-2. PubMed ID: 30604551
    [No Abstract]   [Full Text] [Related]  

  • 4. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.
    Messori A; Becagli P; Trippoli S; Tendi E
    Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of therapies for melanoma.
    Johnston KM; McPherson E; Osenenko K; Vergidis J; Levy AR; Peacock S
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):229-42. PubMed ID: 25703441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the care of the patient with malignant melanoma.
    Reintgen D; Balch CM; Kirkwood J; Ross M
    Ann Surg; 1997 Jan; 225(1):1-14. PubMed ID: 8998115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASO Author Reflections: Stage-Adjusted Reduced Follow-Up of Melanoma Patients is Justified and Cost Effective, Until Biomarkers to Predict Prognosis Have Been Identified.
    Francken AB; Hoekstra-Weebers JEHM; Deckers E; Hoekstra HJ
    Ann Surg Oncol; 2020 May; 27(5):1418-1419. PubMed ID: 31482389
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant therapy for patients with high-risk malignant melanoma.
    McClay EF
    Semin Oncol; 2002 Aug; 29(4):389-99. PubMed ID: 12170442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy of melanoma: at what cost?
    Spitler LE
    J Clin Oncol; 2001 Feb; 19(4):1226-8. PubMed ID: 11181688
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations.
    Verver D; van Klaveren D; van Akkooi ACJ; Rutkowski P; Powell BWEM; Robert C; Testori A; van Leeuwen BL; van der Veldt AAM; Keilholz U; Eggermont AMM; Verhoef C; Grünhagen DJ
    Eur J Cancer; 2018 Jun; 96():25-33. PubMed ID: 29660597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.
    Hillner BE
    Eur J Cancer; 1998 Jul; 34 Suppl 3():S18-21. PubMed ID: 9849404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
    Elliott TM; Whiteman DC; Olsen CM; Gordon LG
    Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant therapy for melanoma.
    Sondak VK; Wolfe JA
    Curr Opin Oncol; 1997 Mar; 9(2):189-204. PubMed ID: 9161800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who benefits most from adjuvant interferon treatment for melanoma?
    Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
    Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant interferon-alpha in malignant melanoma: current status.
    Hancock BW; Harris S; Wheatley K; Gore M
    Cancer Treat Rev; 2000 Apr; 26(2):81-9. PubMed ID: 10772966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma.
    Adam J; Robertson J; Donegan E; Voicechovskaja I
    Lancet Oncol; 2016 Nov; 17(11):1485-1486. PubMed ID: 27692478
    [No Abstract]   [Full Text] [Related]  

  • 17. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trials referral resource. Current trials in melanoma.
    Saxman SB; Smiley JK; Cheson BD
    Oncology (Williston Park); 1999 Sep; 13(9):1239-42. PubMed ID: 10509321
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification and functional validation of therapeutic targets for malignant melanoma.
    Gremel G; Rafferty M; Lau TY; Gallagher WM
    Crit Rev Oncol Hematol; 2009 Dec; 72(3):194-214. PubMed ID: 19328713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Are there specific follow-up modalities recommended in the treatment of stage I melanoma?].
    Fortier-Beaulieu M
    Ann Dermatol Venereol; 1995; 122(5):372-7. PubMed ID: 8572481
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.